10.02.2013 • News

Cedarburg Hauser Adds Controlled Substance Capabilities at Denver Site

Cedarburg Hauser Pharmaceuticals has announced the addition of controlled substance capabilities at its Denver, CO facility. Both of Cedarburg Hauser's facilities, in Colorado and Wisconsin, now hold DEA registrations allowing for the production and analysis of schedule II-V controlled substances.

The kilo-lab manufacturing suites and analytical laboratories at the Denver location are ideal for the development of small molecule APIs, particularly those with unique manufacturing challenges such as potent compounds, controlled substances, and small molecule conjugates.

Cedarburg Hauser specializes in the development and manufacturing of small molecule APIs. We leverage a talented group of scientists and supporting-staff, as well as a centralized approach to project management, to ensure on-time and on-budget completion of projects involving the development, scale-up, and manufacturing of complex APIs.

 

Company

Cedarburg Hauser Pharmaceuticals

870 Badger Circle
WI 53024 Grafton

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.